FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133390842> ?p ?o ?g. }

• W2133390842 endingPage "755" @default.
• W2133390842 startingPage "747" @default.
• W2133390842 abstract "In models of dopaminergic neuronal loss, the dopamine agonist pramipexole has exhibited neuroprotective properties. The Pramipexole On Underlying Disease (PROUD) study was designed to identify whether early versus delayed pramipexole initiation has clinical and neuroimaging benefits in patients with Parkinson's disease (PD).Between May 24, 2006, and April 22, 2009, at 98 centres, we recruited patients with PD diagnosed within 2 years and aged 30-79 years. We randomly assigned eligible patients (ratio 1:1), by a centralised, computerised randomisation schedule, to receive double-blind either placebo or pramipexole (1·5 mg a day) and followed them up for 15 months. At 9 months, or as early as 6 months if considered necessary, placebo recipients were assigned to pramipexole. In a neuroimaging substudy, striatal dopamine-transporter binding was assessed by SPECT. All patients, investigators, and independent raters were masked to study treatment. The primary endpoint was the 15-month change from baseline in total score on the unified Parkinson's disease rating scale (UPDRS). This trial is registered with ClinicalTrials.gov, number NCT00321854.Of 535 patients, 261 were randomly assigned to receive pramipexole and 274 to receive placebo. At 15 months (n=411), adjusted mean change in UPDRS total score showed no significant difference between early and delayed pramipexole (-0·4 points, 95% CI -2·2 to 1·4, p=0·65). 62 patients in the early pramipexole group and 61 patients in the delayed pramipexole group were included in the neuroimaging substudy, for which the adjusted mean 15-month change in striatal (123)I-FP-CIT binding was -15·1% (SE 2·1) for early and -14·6% (2·0) for delayed pramipexole (difference -0·5 percentage points, 95% CI -5·4 to 4·4, p=0·84). Overall, 180 (81%) of patients given early pramipexole and 179 (84%) patients given delayed pramipexole reported adverse events (most frequently nausea), and 22 (10%) patients in the early pramipexole group and 17 (8%) in the delayed pramipexole group had serious events, two of which (hallucinations and orthostatic hypotension) were deemed related to study drug.By clinical and neuroimaging measures, pramipexole showed little evidence differentiating 15-month usage from usage delayed for 6-9 months. The results do not support the hypothesis that pramipexole has disease-modifying effects.Boehringer Ingelheim GmbH." @default.
• W2133390842 created "2016-06-24" @default.
• W2133390842 creator A5005445227 @default.
• W2133390842 creator A5045264162 @default.
• W2133390842 creator A5054027214 @default.
• W2133390842 creator A5054677591 @default.
• W2133390842 creator A5059770430 @default.
• W2133390842 creator A5060095007 @default.
• W2133390842 creator A5062212464 @default.
• W2133390842 creator A5081371583 @default.
• W2133390842 creator A5082083783 @default.
• W2133390842 creator A5087231749 @default.
• W2133390842 creator A5091194111 @default.
• W2133390842 date "2013-08-01" @default.
• W2133390842 modified "2023-09-26" @default.
• W2133390842 title "Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial" @default.
• W2133390842 cites W1533056363 @default.
• W2133390842 cites W1978042435 @default.
• W2133390842 cites W1979969354 @default.
• W2133390842 cites W1997887984 @default.
• W2133390842 cites W2018582283 @default.
• W2133390842 cites W2019300527 @default.
• W2133390842 cites W2021567923 @default.
• W2133390842 cites W2056930405 @default.
• W2133390842 cites W2059621423 @default.
• W2133390842 cites W2063177339 @default.
• W2133390842 cites W2064996887 @default.
• W2133390842 cites W2066514136 @default.
• W2133390842 cites W2068800657 @default.
• W2133390842 cites W2099967870 @default.
• W2133390842 cites W2118825726 @default.
• W2133390842 cites W2130398547 @default.
• W2133390842 cites W2136671766 @default.
• W2133390842 cites W2152727843 @default.
• W2133390842 cites W2154913350 @default.
• W2133390842 cites W2162310837 @default.
• W2133390842 cites W2165370634 @default.
• W2133390842 cites W2301404923 @default.
• W2133390842 cites W2786305788 @default.
• W2133390842 cites W4211223857 @default.
• W2133390842 cites W4233451333 @default.
• W2133390842 cites W4239875825 @default.
• W2133390842 cites W4250151684 @default.
• W2133390842 doi "https://doi.org/10.1016/s1474-4422(13)70117-0" @default.
• W2133390842 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3714436" @default.
• W2133390842 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23726851" @default.
• W2133390842 hasPublicationYear "2013" @default.
• W2133390842 type Work @default.
• W2133390842 sameAs 2133390842 @default.
• W2133390842 citedByCount "163" @default.
• W2133390842 countsByYear W21333908422013 @default.
• W2133390842 countsByYear W21333908422014 @default.
• W2133390842 countsByYear W21333908422015 @default.
• W2133390842 countsByYear W21333908422016 @default.
• W2133390842 countsByYear W21333908422017 @default.
• W2133390842 countsByYear W21333908422018 @default.
• W2133390842 countsByYear W21333908422019 @default.
• W2133390842 countsByYear W21333908422020 @default.
• W2133390842 countsByYear W21333908422021 @default.
• W2133390842 countsByYear W21333908422022 @default.
• W2133390842 countsByYear W21333908422023 @default.
• W2133390842 crossrefType "journal-article" @default.
• W2133390842 hasAuthorship W2133390842A5005445227 @default.
• W2133390842 hasAuthorship W2133390842A5045264162 @default.
• W2133390842 hasAuthorship W2133390842A5054027214 @default.
• W2133390842 hasAuthorship W2133390842A5054677591 @default.
• W2133390842 hasAuthorship W2133390842A5059770430 @default.
• W2133390842 hasAuthorship W2133390842A5060095007 @default.
• W2133390842 hasAuthorship W2133390842A5062212464 @default.
• W2133390842 hasAuthorship W2133390842A5081371583 @default.
• W2133390842 hasAuthorship W2133390842A5082083783 @default.
• W2133390842 hasAuthorship W2133390842A5087231749 @default.
• W2133390842 hasAuthorship W2133390842A5091194111 @default.
• W2133390842 hasBestOaLocation W21333908421 @default.
• W2133390842 hasConcept C126322002 @default.
• W2133390842 hasConcept C137183658 @default.
• W2133390842 hasConcept C142724271 @default.
• W2133390842 hasConcept C168563851 @default.
• W2133390842 hasConcept C199596767 @default.
• W2133390842 hasConcept C203092338 @default.
• W2133390842 hasConcept C204787440 @default.
• W2133390842 hasConcept C27081682 @default.
• W2133390842 hasConcept C2778258207 @default.
• W2133390842 hasConcept C2779134260 @default.
• W2133390842 hasConcept C2779734285 @default.
• W2133390842 hasConcept C2779989193 @default.
• W2133390842 hasConcept C513476851 @default.
• W2133390842 hasConcept C71924100 @default.
• W2133390842 hasConceptScore W2133390842C126322002 @default.
• W2133390842 hasConceptScore W2133390842C137183658 @default.
• W2133390842 hasConceptScore W2133390842C142724271 @default.
• W2133390842 hasConceptScore W2133390842C168563851 @default.
• W2133390842 hasConceptScore W2133390842C199596767 @default.
• W2133390842 hasConceptScore W2133390842C203092338 @default.
• W2133390842 hasConceptScore W2133390842C204787440 @default.
• W2133390842 hasConceptScore W2133390842C27081682 @default.
• W2133390842 hasConceptScore W2133390842C2778258207 @default.
• W2133390842 hasConceptScore W2133390842C2779134260 @default.

• next